An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma
Completed
The purpose of this study is to evaluate the safety and effectiveness of several combination therapies for Multiple Myeloma. Upon entry into the study, patients will be randomized (assigned by chance) to receive either: Group 1: nivolumab, pomalidomide and dexamethasone OR Group 2: pomalidomide and dexamethasone OR Group 3: nivolumab, elotuzumab, pomalidomide and dexamethasone. Enrollment is closed for all groups.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2023
Locations: Local Institution - 0020, Birmingham, Alabama +120 locations
Conditions: Multiple Myeloma
A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma
Terminated
This is an open-label, multicenter study to confirm the safety and efficacy of durvalumab + daratumumab (D2) in subjects with relapsed and refractory multiple myeloma. This study will also explore the safety and efficacy of the addition of pomalidomide + dexamethasone to durvalumab + daratumumab (PD3). On 05 Sep 2017, a Partial Clinical Hold was placed on this study by the United States (US) Food and Drug Administration (FDA). The decision by the FDA was based on data related to risks of anti-p... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/16/2023
Locations: City of Hope National Medical Center, Duarte, California +63 locations
Conditions: Multiple Myeloma
A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Completed
The purpose of this study is to determine whether the addition of oral ixazomib to the background therapy of lenalidomide and dexamethasone improves progression free survival (PFS) in participants with relapsed and/or refractory multiple myeloma (RRMM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/07/2023
Locations: University of Arkansas Medical Sciences, Little Rock, Arkansas +23 locations
Conditions: Relapsed Multiple Myeloma, Refractory Multiple Myeloma
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
Active Not Recruiting
This is a multicenter, randomized, open-label, Phase 3 study comparing the efficacy and safety of bb2121 versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM). The study is anticipated to randomize approximately 381 subjects with RRMM. Approximately 254 subjects will be randomized to Treatment Arm A and approximately 127 subjects will be randomized to Treatment Arm B.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/13/2022
Locations: Local Institution - 109, Birmingham, Alabama +59 locations
Conditions: Multiple Myeloma
High Dose Steroids for Dysphagia
Withdrawn
Few existing data currently indicates that anti-inflammatory drugs could help diminish the local cervical inflammation tough to cause the dysphagia, hoarseness and dyspnea after an anterior surgical approach to the spine. This study aims to evaluate the effect of high dose of steroids on dysphagia after an anterior cervical spine procedure. Patients subjected to a cervical spine surgery through an anterior approach will be randomized to a treatment group receiving 3 doses of IV dexamethasone (de... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2022
Locations: Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec
Conditions: Dysphagia, Cervical Spine Disease
A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma
Completed
The main aim of this study is to learn if ixazomib, given with dexamethasone, stops the cancer from getting worse in people with relapsed or refractory multiple myeloma. It will be compared to another medicine called pomalidomide, given with dexamethasone with people with the same condition. Relapsed means the previous cancer treatment stopped working, over time. Refractory means they did not respond to previous cancer treatment. Another aim is to check for side effects from the study medicines.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/21/2022
Locations: Highlands Oncology Group, Fayetteville, Arkansas +110 locations
Conditions: Relapsed and/or Refractory Multiple Myeloma
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
Completed
The primary objective of this study was to compare progression-free survival in patients with multiple myeloma who relapsed after 1 to 3 prior therapies treated with carfilzomib plus dexamethasone or bortezomib plus dexamethasone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/10/2022
Locations: Providence St. Joseph Medical Center, Burbank, California +240 locations
Conditions: Multiple Myeloma
A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
Terminated
The purpose of this study is to confirm that the pharmacokinetics of ibrutinib in pediatric participants is consistent with that in adults (part 1) and to assess efficacy (event-free survival \[EFS\]) of ibrutinib in combination with rituximab, ifosfamide, carboplatin, and etoposide (RICE) or rituximab, vincristine, ifosfamide, carboplatin, and idarubicin (RVICI) background therapy compared to RICE or RVICI background therapy alone (part 2).
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
11/07/2022
Locations: Not set, Los Angeles, California +76 locations
Conditions: Lymphoma, Non-Hodgkin
Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)
Completed
The purpose of this study is to determine the pharmacokinetics (PK) and safety for the combination of pomalidomide (POM) + low-dose dexamethasone (LD- DEX) in subjects with relapsed or refractory Multiple Myeloma (RRMM) and impaired renal function.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/03/2022
Locations: Colorado Blood Cancer Institute, Denver, Colorado +8 locations
Conditions: Multiple Myeloma, Renal Impairment
An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)
Completed
The purpose of this study is to determine if adding Elotuzumab to Pomalidomide and low-dose dexamethasone is a more effective treatment of relapsed and refractory multiple myeloma compared to pomalidomide and low-dose dexamethasone by itself.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/05/2022
Locations: Winship Cancer Institute, Atlanta, Georgia +54 locations
Conditions: Multiple Myeloma
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
Completed
The purpose of the study is to compare the progression-free survival (PFS) of once-weekly carfilzomib dosing in combination with dexamethasone to twice-weekly carfilzomib dosing in combination with dexamethasone in adults with relapsed and refractory multiple myeloma, previously treated with bortezomib and an immunomodulatory agent (IMiD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/09/2022
Locations: Research Site, Scottsdale, Arizona +139 locations
Conditions: Multiple Myeloma
Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma
Completed
The primary objective was to compare progression-free survival in adults with relapsed multiple myeloma who are receiving CRd vs participants receiving Rd in a randomized multicenter setting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/08/2022
Locations: Mayo Clinic, Scottsdale, Arizona +126 locations
Conditions: Relapsed Multiple Myeloma